SYNTHESIS OF SOME NEW THIENO[2,3-<i>b</i>]PYRIDINES, PYRIDO[3′,2′:4,5]-THIENO[3,2-<i>d</i>]PYRIMIDINES AND PYRIDO[3′,2′:4,5]THIENO[3,2-<i>d</i>][1,2,3]-TRIAZINES
作者:A. E. Abdel-rahman、E. A. Bakhite、O. S. Mohamed、E. A. Thabet
DOI:10.1080/10426500008076538
日期:2000.1.1
Thorpe-Ziegler cyclization to afford the corresponding 3-amino-4-aryl-2-functionallized-cyclopenta[e]thieno [2,3-b]pyridines (5a-c and 6a-i). Most of the latter thienopyridines were used as synthons for the target cyclopenta[5′,6′]pyrido[3′,2′:4.5]thieno[3,2-d]pyrimidines and cyclopenta[5′,6′]. pyrido[3′,2′:4,5]thieno[3,2-d][1,2,3]triazines.
for multisubstituted pyridines from β-aryl-substituted α,β-unsaturated oxime ethers and alkenes via Pd-catalyzed C–H activation has been developed. Systematic optimization of catalyst ligands revealed that sterically hindered pyridines increased the reactivity. Mechanistic studies suggested that the products are formed by Pd-catalyzed β-alkenylation of α,β-unsaturated oxime followed by aza-6π-electrocyclization
A new type of ferrocene-based phosphine-oxazoline ligand has been prepared over a few simple steps. An iridium complex of this ligand is air stable and exhibits excellent performance for the asymmetric hydrogenation of simple ketones (up to 98% yield, up to 99% ee, and 20 000 S/C). Exo-α,β-unsaturated cyclic ketones could be regiospecifically hydrogenated to give chiral allylic alcohols with good results
通过几个简单的步骤即可制备出新型的二茂铁基膦-恶唑啉配体。该配体的铱络合物是空气稳定的,并且对于简单的酮的不对称氢化表现出出色的性能(最高98%的收率,最高99%的ee和20000 S / C)。Exo -α,β-不饱和环状酮可被区域特异性氢化,得到手性烯丙基醇,效果良好。这项研究表明,P,N-配体也可以有效地促进Ir催化的不对称氢化反应,而无需NH-氢键辅助。
[EN] ACYLSUFONAMIDE COMPOUNDS USEFUL AS EP3 RECEPTOR ANTAGONISTS<br/>[FR] COMPOSÉS D'ACYLSUFONAMIDE UTILES EN TANT QU'ANTAGONISTES DU RÉCEPTEUR EP3
申请人:JANSSEN PHARMACEUTICA NV
公开号:WO2020008317A1
公开(公告)日:2020-01-09
The present invention is directed to acylsulfonamide derivatives of formula (I), pharmaceutical compositions containing them and their use as antagonists of the EP3 receptor, for the treatment of, for example, impaired oral glucose tolerance, elevated fasting glucose, Type II Diabetes Mellitus, Syndrome X (also known as Metabolic Syndrome) and related disorders and complications thereof.
metconazole have many disadvantages, for example, requiring multiple steps, being complicated, and suffering from high cost. We report herein a new, convenient, and high-yield four-step (aldol condensation, dimethylation, hydrogenation, and one-pot triazolation) synthesis for metconazole with relatively low cost.